Literature DB >> 16042910

New insights into the pathophysiology of irritable bowel syndrome: implications for future treatments.

Michael D Crowell1, Lucinda Harris, Michael P Jones, Lin Chang.   

Abstract

Irritable bowel syndrome (IBS) is a multifactorial disorder characterized by abdominal pain and altered bowel habits. Chronic symptoms may occur due to changes in gastrointestinal motor function, enhanced perception of gut stimuli, and psychosocial factors. Recent data suggest that abnormal processing of afferent signals occurs in IBS patients. A newly recognized causative factor in a subset of IBS patients is post-infectious IBS. Altered transport of intestinal gas and bowel distention may contribute to abdominal discomfort, pain, and bloating. Changes in gut microflora have also been reported, but data remain scant. Advances have been made in our understanding of serotonin signaling and metabolism in IBS patients, in part due to the introduction of specific receptor agonists and antagonists. Finally, exciting data are emerging on genetic alterations that may contribute to the pathophysiology and treatment of IBS. Increasingly novel mechanisms are being identified that should aid in better understanding of the complex pathophysiology of IBS and developing new therapies.

Entities:  

Mesh:

Year:  2005        PMID: 16042910     DOI: 10.1007/s11894-005-0019-8

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  71 in total

1.  Slowing of intestinal transit by fat depends on an ondansetron - sensitive, efferent serotonergic pathway.

Authors:  H C Lin; J H Chen
Journal:  Neurogastroenterol Motil       Date:  2003-06       Impact factor: 3.598

Review 2.  Does past pain influence current pain: biological and psychosocial models of sex differences.

Authors:  Gary B Rollman; Jennifer Abdel-Shaheed; Joanne M Gillespie; Kevin S Jones
Journal:  Eur J Pain       Date:  2004-10       Impact factor: 3.931

3.  Functional dyspepsia and irritable bowel syndrome: is there a common pathophysiological basis?

Authors:  G Holtmann; H Goebell; N J Talley
Journal:  Am J Gastroenterol       Date:  1997-06       Impact factor: 10.864

4.  Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention.

Authors:  H Mertz; V Morgan; G Tanner; D Pickens; R Price; Y Shyr; R Kessler
Journal:  Gastroenterology       Date:  2000-05       Impact factor: 22.682

5.  Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors.

Authors:  Magnus Simrén; Jenny Axelsson; Rolf Gillberg; Hasse Abrahamsson; Jan Svedlund; Einar S Björnsson
Journal:  Am J Gastroenterol       Date:  2002-02       Impact factor: 10.864

6.  Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials.

Authors:  F Cremonini; S Delgado-Aros; M Camilleri
Journal:  Neurogastroenterol Motil       Date:  2003-02       Impact factor: 3.598

7.  Sex differences in temporal summation of pain and aftersensations following repetitive noxious mechanical stimulation.

Authors:  Eleni Sarlani; Edward G Grace; Mark A Reynolds; Joel D Greenspan
Journal:  Pain       Date:  2004-05       Impact factor: 6.961

8.  Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis.

Authors:  L-H Wang; X-C Fang; G-Z Pan
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

9.  An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome.

Authors:  J Kellow; O Y Lee; F Y Chang; S Thongsawat; M Z Mazlam; H Yuen; K A Gwee; Y T Bak; J Jones; A Wagner
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

10.  Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans.

Authors:  Silvia Delgado-Aros; Heather J Chial; Michael Camilleri; Lawrence A Szarka; Frank T Weber; Jutta Jacob; Irene Ferber; Sanna McKinzie; Duane D Burton; Alan R Zinsmeister
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2003-04       Impact factor: 4.052

View more
  11 in total

1.  Analgesic effect of Coptis chinensis rhizomes (Coptidis Rhizoma) extract on rat model of irritable bowel syndrome.

Authors:  Yungwui Tjong; Siupo Ip; Lixing Lao; Harry H S Fong; Joseph J Y Sung; Brian Berman; Chuntao Che
Journal:  J Ethnopharmacol       Date:  2011-04-12       Impact factor: 4.360

Review 2.  Diagnosis and management of IBS.

Authors:  Sarah Khan; Lin Chang
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10       Impact factor: 46.802

3.  Novel Therapies in IBS-D Treatment.

Authors:  Judy Nee; Mohammed Zakari; Anthony J Lembo
Journal:  Curr Treat Options Gastroenterol       Date:  2015-12

Review 4.  Defecation disorders: neuromuscular aspects and treatment.

Authors:  Jose M Remes-Troche; Satish S C Rao
Journal:  Curr Gastroenterol Rep       Date:  2006-08

Review 5.  The role of stress on physiologic responses and clinical symptoms in irritable bowel syndrome.

Authors:  Lin Chang
Journal:  Gastroenterology       Date:  2011-01-19       Impact factor: 22.682

Review 6.  Recent advances in pharmacological treatment of irritable bowel syndrome.

Authors:  Georgia Lazaraki; Grigoris Chatzimavroudis; Panagiotis Katsinelos
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

7.  Cyclic stretch disrupts apical junctional complexes in Caco-2 cell monolayers by a JNK-2-, c-Src-, and MLCK-dependent mechanism.

Authors:  Geetha Samak; Ruchika Gangwar; Lynn M Crosby; Leena P Desai; Kristina Wilhelm; Christopher M Waters; RadhaKrishna Rao
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-04-10       Impact factor: 4.052

Review 8.  Chronic functional bowel syndrome enhances gut-brain axis dysfunction, neuroinflammation, cognitive impairment, and vulnerability to dementia.

Authors:  Mak Adam Daulatzai
Journal:  Neurochem Res       Date:  2014-03-04       Impact factor: 3.996

9.  Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome.

Authors:  William D Chey; Monthira Maneerattaporn; Richard Saad
Journal:  Gut Liver       Date:  2011-08-18       Impact factor: 4.519

10.  Correlation between gastrointestinal hormones and anxiety-depressive states in irritable bowel syndrome.

Authors:  Baojuan Han
Journal:  Exp Ther Med       Date:  2013-07-09       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.